A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy

A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy

Treatments using immune checkpoint inhibitors such as pembrolizumab lead to immune mediated adverse effects including hemophagocytic lymphohistiocytosis (HLH). Herein, we present a case where HLH developed after pembrolizumab administration, which was treated using high dose prednisolone. He develop...

Full description

Bibliographic Details
Main Authors: Hidenori Takahashi, Tomohiro Koiwa, Akira Fujita, Takayuki Suzuki, Amane Tagashira, Yoshinobu Iwasaki
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Respiratory Medicine Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S221300712030174X

Similar Items

Similar Items